Heidelberg Pharma

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Heidelberg Pharma sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,751 sponsors by registered trial count).

5 total trials 1 currently recruiting 4 completed upper quartile by trial count

Heidelberg Pharma: 5 sponsored US clinical trials, 1 recruiting.

Heidelberg Pharma sponsors 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Plasma Cell Disorder, with 1 trials.

Upper-quartile sponsor footprint

Heidelberg Pharma sits in the upper quartile of the sponsor corpus (#2,411 of 15,751 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Heidelberg Pharma pipeline

1 recruiting of 5 indexed (20% open); 4 completed (80%).

Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Plasma Cell Disorder (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.